Novo Nordisk ® — improving insurance access for your patients
Novoeight ® is now preferred a on
• United Healthcare formulary
• CVS Caremark formulary
Helixate ® is no longer preferred on these plans as of January 2017 .
a
Formulary status subject to change . Multiple products within the same therapeutic class may be considered “ preferred ” and on the same tier . This information should not be used to make efficacy or safety comparisons between or among mentioned products .
8
PTPs
years of clinical experience with Novoeight ® in PTPs 1
= previously treated patients .
Talk to a Novo Nordisk Representative about Novoeight ® coverage in your area . Visit www . Novoeightpro . com .
Indications and Usage
Novoeight ® ( Antihemophilic Factor [ Recombinant ]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding , perioperative management , and routine prophylaxis to prevent or reduce the frequency of bleeding episodes .
Novoeight ® is not indicated for the treatment of von Willebrand disease .
Important Safety Information
Do not use in patients who have had life-threatening hypersensitivity reactions , including anaphylaxis , to Novoeight ® or its components , including hamster proteins .
Anaphylaxis and severe hypersensitivity reactions are possible . Patients may develop hypersensitivity to hamster proteins , which are present in trace amounts in the product . Should symptoms occur , discontinue Novoeight ® and administer appropriate treatment .
Development of activity-neutralizing antibodies ( inhibitors ) may occur . If expected plasma factor VIII activity levels are not attained , or if bleeding is not controlled with an appropriate dose , perform an assay that measures factor VIII inhibitor concentration .
The most frequently reported adverse reactions ( ≥0.5 %) were injection site reactions , increased hepatic enzymes , and pyrexia .
Please see brief summary of Prescribing Information on following page .
Reference : 1 . Lentz SR , Misgav M , Ozelo M , et al . Results from a large multinational clinical trial ( guardian ™ 1 ) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A : safety and efficacy . Haemophilia . 2013 ; 19 ( 5 ): 691-697 .
Novo Nordisk Inc ., 800 Scudders Mill Road , Plainsboro , New Jersey 08536 U . S . A .
Novoeight ® is a registered trademark of Novo Nordisk Health Care AG . Novo Nordisk is a registered trademark of Novo Nordisk A / S . © 2017 Novo Nordisk All rights reserved . USA17BIO00293 March 2017